189 related articles for article (PubMed ID: 8819585)
61. Protease inhibitors...the best thing since...?
Servilio J
Posit Aware; 1995; ():16-9. PubMed ID: 11362662
[TBL] [Abstract][Full Text] [Related]
62. HIV protease inhibition: limited recent progress and advances in understanding current pitfalls.
Rodríguez-Barrios F; Gago F
Curr Top Med Chem; 2004; 4(9):991-1007. PubMed ID: 15134553
[TBL] [Abstract][Full Text] [Related]
63. Caught in the act. Femtochemistry opens the lid on biology's third vital criterion.
Hunter P
EMBO Rep; 2013 Jan; 14(1):36-8. PubMed ID: 23229588
[No Abstract] [Full Text] [Related]
64. Testing time as resistant HIV-1 faces next wave of attack.
Mellors J
Lancet; 1999 Jul; 354(9173):135. PubMed ID: 10408499
[No Abstract] [Full Text] [Related]
65. An efficient synthesis of a hydroxyethylamine (HEA) isostere and its α-aminophosphonate and phosphoramidate derivatives as potential anti-HIV agents.
Bhattacharya AK; Rana KC; Pannecouque C; De Clercq E
ChemMedChem; 2012 Sep; 7(9):1601-11. PubMed ID: 22786810
[TBL] [Abstract][Full Text] [Related]
66. Cage dimeric 4-aryl-1,4-dihydropyridines as promising lead structures for the development of a novel class of HIV-1 protease inhibitors.
Hilgeroth A; Billich A
Arch Pharm (Weinheim); 1999 Jan; 332(1):3-5. PubMed ID: 10073137
[No Abstract] [Full Text] [Related]
67. Significance of P-glycoprotein for the pharmacology and clinical use of HIV protease inhibitors.
Huisman MT; Smit JW; Schinkel AH
AIDS; 2000 Feb; 14(3):237-42. PubMed ID: 10716499
[No Abstract] [Full Text] [Related]
68. Rational drug design and HIV: hopes and limitations.
Goody RS
Nat Med; 1995 Jun; 1(6):519-20. PubMed ID: 7585113
[No Abstract] [Full Text] [Related]
69. HIV drug resistance.
Voelker R
JAMA; 2000 Jul; 284(2):169. PubMed ID: 10917789
[No Abstract] [Full Text] [Related]
70. Reversibility of HIV drug resistance.
Davenport MP
Science; 2000 May; 288(5470):1299. PubMed ID: 10847833
[No Abstract] [Full Text] [Related]
71. Synthesis and biological evaluation in vitro and in mammalian cells of new heteroaryl carboxyamides as HIV-protease inhibitors.
Funicello M; Chiummiento L; Tramutola F; Armentano MF; Bisaccia F; Miglionico R; Milella L; Benedetti F; Berti F; Lupattelli P
Bioorg Med Chem; 2017 Sep; 25(17):4715-4722. PubMed ID: 28739156
[TBL] [Abstract][Full Text] [Related]
72. Design and synthesis of selenazole-substituted ritonavir analogs.
Qiao J; Zhao C; Liu J; Du Y
Bioorg Med Chem Lett; 2018 Aug; 28(14):2379-2381. PubMed ID: 29934245
[TBL] [Abstract][Full Text] [Related]
73. Concentration-targeted therapy and the future of HIV management.
Flexner CW; Piscitelli SC
AIDS; 2002 Mar; 16 Suppl 1():S1-3. PubMed ID: 12035819
[No Abstract] [Full Text] [Related]
74. Synthesis and biological evaluation of novel isopropanolamine derivatives as non-peptide human immunodeficiency virus protease inhibitors.
Zhou L; Yang Q; Wang Y; Hu Y; Luo X; Bai D; Li S
Chem Pharm Bull (Tokyo); 2008 Aug; 56(8):1147-52. PubMed ID: 18670116
[TBL] [Abstract][Full Text] [Related]
75. HIV-1 protease: mechanism and drug discovery.
Brik A; Wong CH
Org Biomol Chem; 2003 Jan; 1(1):5-14. PubMed ID: 12929379
[No Abstract] [Full Text] [Related]
76. Inhibitor-resistant mutants of the HIV-1 aspartic protease.
Korant BD
Adv Exp Med Biol; 1995; 362():407-11. PubMed ID: 8540350
[No Abstract] [Full Text] [Related]
77. Protease inhibitors in the homeless.
Bangsberg D; Tulsky JP; Hecht FM; Moss AR
JAMA; 1997 Jul; 278(1):63-5. PubMed ID: 9207341
[No Abstract] [Full Text] [Related]
78. A rapid and simple screening method for HIV-1 protease inhibitors using recombinant Escherichia coli.
Kaneto R; Kojima I; Shibamoto N; Nishida H; Okamoto R; Akagawa H; Mizuno S
J Antibiot (Tokyo); 1994 Apr; 47(4):492-5. PubMed ID: 8195050
[No Abstract] [Full Text] [Related]
79. 5th International Workshop on HIV Drug Resistance & Treatment Strategies. 4-8 June 2001, Scottsdale, Arizona. Abstracts.
Antivir Ther; 2001; 6 Suppl 1():1-141. PubMed ID: 11439941
[No Abstract] [Full Text] [Related]
80. Targeting HIV-1 protease: a test of drug-design methodologies.
West ML; Fairlie DP
Trends Pharmacol Sci; 1995 Feb; 16(2):67-75. PubMed ID: 7762084
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
